BofA raised the firm’s price target on Regeneron (REGN) to $543 from $504 and keeps an Underperform rating on the shares. In a “strong Q2,” the only negatives were more delays in regulatory approval with Eylea HD formulation and odronextamab, though these “may be short-lived,” the analyst tells investors in a post-earnings note. The firm has felt consensus forecasts could be at risk from faster-than-expected Eylea erosion, but Friday’s performance was “encouraging,” the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Positive Indicators and Strategic Investments Support Buy Rating for Regeneron
- Regeneron price target raised to $761 from $754 at Morgan Stanley
- Regeneron price target raised to $753 from $750 at Bernstein
- Cautious Outlook on Regeneron Despite Strong Performance: Sell Rating Due to Potential Eylea Erosion and Medicare Risks
- Regeneron Pharmaceuticals Reports Strong Q2 2025 Results